CN111094340A - 抗Abeta抗体、其抗原结合片段及应用 - Google Patents

抗Abeta抗体、其抗原结合片段及应用 Download PDF

Info

Publication number
CN111094340A
CN111094340A CN201980004496.0A CN201980004496A CN111094340A CN 111094340 A CN111094340 A CN 111094340A CN 201980004496 A CN201980004496 A CN 201980004496A CN 111094340 A CN111094340 A CN 111094340A
Authority
CN
China
Prior art keywords
seq
antibody
amino acid
antigen
set forth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980004496.0A
Other languages
English (en)
Other versions
CN111094340B (zh
Inventor
应华
张玲
石金平
张小敏
孙嘉康
胡齐悦
陶维康
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of CN111094340A publication Critical patent/CN111094340A/zh
Application granted granted Critical
Publication of CN111094340B publication Critical patent/CN111094340B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

具有特定CDR区的鼠源、嵌合或人源化的抗Abeta抗体及其抗原结合片段，其药物组合物，及其用途。一种人源化的抗Abeta抗体在制备用于治疗β淀粉样蛋白引起的疾病或病症(例如，阿尔茨海默病)的药物中的用途。

Description

PCT国内申请，说明书已公开。

Claims (22)

  1. PCT国内申请，权利要求书已公开。
CN201980004496.0A 2018-07-17 2019-07-16 抗Abeta抗体、其抗原结合片段及应用 Active CN111094340B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018107821962 2018-07-17
CN201810782196 2018-07-17
PCT/CN2019/096159 WO2020015637A1 (zh) 2018-07-17 2019-07-16 抗Abeta抗体、其抗原结合片段及应用

Publications (2)

Publication Number Publication Date
CN111094340A true CN111094340A (zh) 2020-05-01
CN111094340B CN111094340B (zh) 2022-11-22

Family

ID=69163622

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980004496.0A Active CN111094340B (zh) 2018-07-17 2019-07-16 抗Abeta抗体、其抗原结合片段及应用

Country Status (10)

Country Link
US (1) US20210371506A1 (zh)
EP (1) EP3819311A4 (zh)
JP (1) JP7436449B2 (zh)
KR (1) KR20210032408A (zh)
CN (1) CN111094340B (zh)
AU (1) AU2019304384A1 (zh)
BR (1) BR112020027055A2 (zh)
CA (1) CA3106116A1 (zh)
MX (1) MX2021000235A (zh)
WO (1) WO2020015637A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117624358A (zh) * 2024-01-26 2024-03-01 南京诺唯赞医疗科技有限公司 Aβ1-40特异性抗体及其在阿尔茨海默症辅助诊断试剂盒的应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021310926A1 (en) 2020-07-23 2023-03-23 Othair Prothena Limited Anti-abeta antibodies

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001241786A1 (en) * 2000-02-24 2001-11-15 Eli Lilly And Company Humanized antibodies that sequester abeta peptide
CN1849139A (zh) * 2002-10-09 2006-10-18 里纳特神经系统学公司 使用针对淀粉样β肽的抗体及其组合物治疗阿尔茨海默氏病的方法
CN101325972A (zh) * 2005-12-12 2008-12-17 Ac免疫有限公司 具有治疗性质的Aβ1-42特异性单克隆抗体
CN105924521A (zh) * 2005-11-30 2016-09-07 Abbvie 公司 抗-Aβ球聚体抗体，其相关产品，生产所述抗体的方法，所述抗体的应用以及使用方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5750349A (en) 1993-01-25 1998-05-12 Takeda Chemical Industries Ltd. Antibodies to β-amyloids or their derivatives and use thereof
AU743827B2 (en) 1997-04-09 2002-02-07 Intellect Neurosciences, Inc. Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof
JP2005503789A (ja) 2001-08-17 2005-02-10 イーライ・リリー・アンド・カンパニー 抗Ａβ抗体
AR038568A1 (es) 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
EP1633786A4 (en) 2002-10-09 2007-07-25 Rinat Neuroscience Corp METHOD FOR TREATING ALZHEIMER DISEASE WITH ANTIBODIES TO AMYLOID BETA PEPTIDE AND COMPOSITIONS THEREOF
DE602004027348D1 (de) 2003-02-10 2010-07-08 Applied Molecular Evolution Abeta-bindende moleküle
TWI374893B (en) * 2003-05-30 2012-10-21 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US7906625B2 (en) 2005-01-24 2011-03-15 Amgen Inc. Humanized anti-amyloid antibody
KR101413615B1 (ko) 2006-03-23 2014-07-18 바이오악틱 뉴로사이언스 에이비 인간 프로토피브릴에 선택적인 개선된 항체 및 이의 용도
EP2177536B1 (en) * 2006-03-30 2014-06-04 Glaxo Group Limited Antibodies against amyloid-beta peptide
AU2007275467B2 (en) 2006-07-14 2013-12-05 Ac Immune S.A. Humanized antibody against amyloid beta
CN103408661B (zh) 2007-01-05 2016-04-06 苏黎世大学 提供疾患特异性结合分子和靶的方法
AU2008311365B2 (en) * 2007-10-05 2015-03-12 Ac Immune S.A. Humanized antibody
JP5812418B2 (ja) 2009-04-17 2015-11-11 イムナス・ファーマ株式会社 Ａβオリゴマーに特異的に結合する抗体およびその利用
AU2011315920B2 (en) 2010-10-15 2016-04-28 The Board Of Regents Of The University Of Texas System Antibodies that bind amyloid oligomers
US9834598B2 (en) * 2012-10-15 2017-12-05 Medimmune Limited Antibodies to amyloid beta
TW201728603A (zh) 2016-02-05 2017-08-16 江蘇恆瑞醫藥股份有限公司 凝血酶抗體、其抗原結合片段及醫藥用途
CN116333108A (zh) * 2016-07-18 2023-06-27 英属哥伦比亚大学 淀粉样蛋白β的抗体

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001241786A1 (en) * 2000-02-24 2001-11-15 Eli Lilly And Company Humanized antibodies that sequester abeta peptide
CN1849139A (zh) * 2002-10-09 2006-10-18 里纳特神经系统学公司 使用针对淀粉样β肽的抗体及其组合物治疗阿尔茨海默氏病的方法
CN105924521A (zh) * 2005-11-30 2016-09-07 Abbvie 公司 抗-Aβ球聚体抗体，其相关产品，生产所述抗体的方法，所述抗体的应用以及使用方法
CN101325972A (zh) * 2005-12-12 2008-12-17 Ac免疫有限公司 具有治疗性质的Aβ1-42特异性单克隆抗体

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117624358A (zh) * 2024-01-26 2024-03-01 南京诺唯赞医疗科技有限公司 Aβ1-40特异性抗体及其在阿尔茨海默症辅助诊断试剂盒的应用
CN117624358B (zh) * 2024-01-26 2024-04-12 南京诺唯赞医疗科技有限公司 Aβ1-40特异性抗体及其在阿尔茨海默症辅助诊断试剂盒的应用

Also Published As

Publication number Publication date
WO2020015637A1 (zh) 2020-01-23
MX2021000235A (es) 2021-03-25
KR20210032408A (ko) 2021-03-24
CN111094340B (zh) 2022-11-22
CA3106116A1 (en) 2020-01-23
EP3819311A4 (en) 2022-08-17
JP7436449B2 (ja) 2024-02-21
BR112020027055A2 (pt) 2021-04-06
JP2021529543A (ja) 2021-11-04
AU2019304384A1 (en) 2021-01-28
EP3819311A1 (en) 2021-05-12
US20210371506A1 (en) 2021-12-02

Similar Documents

Publication Publication Date Title
CN111051347B (zh) Tigit抗体、其抗原结合片段及医药用途
US10364286B2 (en) Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
JP7061875B2 (ja) アミロイドベータタンパク質に対するモノクローナル抗体及びその使用
CN109937212B (zh) B7-h3抗体、其抗原结合片段及其医药用途
CN108472349A (zh) Lag-3抗体、其抗原结合片段及其医药用途
WO2019091449A1 (zh) Cd96抗体、其抗原结合片段及医药用途
CN101432302A (zh) 抗－Aβ球聚体抗体，其抗原结合部分，相应的杂交瘤、核酸、载体、宿主细胞，生产所述抗体的方法，包含所述抗体的组合物，所述抗体的应用以及使用所述抗体的方法
CN101925611A (zh) Wise结合剂和表位
US20220340654A1 (en) Antibody capable of binding to thymic stromal lymphopoietin and use thereof
CN105111310A (zh) 抗nogo-66受体(ngr)的中和单克隆抗体及其用途
JP2018139530A (ja) 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
CN114829395B (zh) 抗angptl3抗体及其应用
JP2022526487A (ja) Ｖｅｇｆ及びａｎｇ２に特異的に結合する二重特異性抗体
CN111094340A (zh) 抗Abeta抗体、其抗原结合片段及应用
CN113840836A (zh) 抗结缔组织生长因子抗体及其应用
WO2019096294A1 (zh) 凝血酶抗体、其抗原结合片段及医药用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant